Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phico Therapeutics details phase I tolerability of PT1.2

Sep. 27, 2010

BI-10773 improves glycemic control in large study in type 2 diabetes

Sep. 27, 2010

Novartis reports on clinical development of LDE-225

Sep. 27, 2010

Interim phase I/II data suggest safety of everolimus in advanced HCC

Sep. 27, 2010

Phase I data presented on hypnotic agent GF-015535-00

Sep. 27, 2010

New vancomycin carbamate derivative shows potent antibacterial activity in drug-resistant strains

Sep. 23, 2010

Favorable safety and pharmacokinetics seen in phase I trials of anti-CMV agent AIC-246

Sep. 23, 2010

Multiple dosing of AMG-853 well tolerated in healthy volunteers

Sep. 23, 2010

High loading dose of clopidogrel may overcome effects of CYP2C19 genetic variant in persons with CAD

Sep. 23, 2010

Fixed-dose fenofibrate/pravastatin plus ezetimibe reduces hyperlipidemia in type 2 diabetes

Sep. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...